STAAR Surgical reported strong 1Q26 results, with revenue rising 119% year-over-year to $93.5 million and a net income of $5.2 million, reversing previous losses. Growth was driven by China's market recovery, normalized inventory levels, and rapid adoption of the EVO+ ICL lens. The company benefits from a shift toward lens-based refractive surgery, gaining U.S. market share despite a shrinking laser market and expanding its addressable market with FDA approval. While valuation remains high, sustained revenue growth and margin expansion are needed to justify current multiples.
ImPact Biotech announced updated Phase 3 ENLIGHTED trial results showing 70% complete response in patients with low-grade upper tract urothelial carcinoma (UTUC) treated with Padeliporfin VTP. The treatment demonstrated durable effects, with 85.7% of...
Bitcoin's price dropped below $78,000 after a brief rally above $82,000 triggered by the US Senate Banking Committee's advancement of the Digital Asset Market Clarity Act. The decline reflects renewed macroeconomic pressures, including rising US 10-y...
Terreno Realty Corporation (TRNO) is rated a Buy with a $70 price target due to strong Q1 2026 earnings and a solid development pipeline. The company's focus on infill, supply-constrained coastal markets supports high occupancy rates (96.3%) and stea...
Concerns over high energy prices and ongoing geopolitical conflicts, especially involving Iran, have led to a sell-off in long-term government bonds, pushing the US 10-year Treasury yield close to 4.6%. This rise increases borrowing costs for consume...
Grayscale and VanEck have filed amendments to their Spot Binance Coin (BNB) ETF applications with the SEC, indicating progress toward approval. Bloomberg analyst James Seyffart noted these updates suggest feedback from the SEC and a potential near-fu...
